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RNA-Seq analysis implicates dysregulation of the
immune system in schizophrenia
Junzhe Xu1,2,3†, Jingchun Sun4,5†, Jingchun Chen6, Lily Wang7, Anna Li2, Matthew Helm2, Steven L Dubovsky1,
Silviu-Alin Bacanu6, Zhongming Zhao4,5,8*, Xiangning Chen6,9*
From The International Conference on Intelligent Biology and Medicine (ICIBM)
Nashville, TN, USA. 22-24 April 2012

Abstract
Background: While genome-wide association studies identified some promising candidates for schizophrenia, the
majority of risk genes remained unknown. We were interested in testing whether integration gene expression and
other functional information could facilitate the identification of susceptibility genes and related biological pathways.
Results: We conducted high throughput sequencing analyses to evaluate mRNA expression in blood samples isolated
from 3 schizophrenia patients and 3 healthy controls. We also conducted pooled sequencing of 10 schizophrenic
patients and matched controls. Differentially expressed genes were identified by t-test. In the individually sequenced
dataset, we identified 198 genes differentially expressed between cases and controls, of them 19 had been verified by
the pooled sequencing dataset and 21 reached nominal significance in gene-based association analyses of a genome
wide association dataset. Pathway analysis of these differentially expressed genes revealed that they were highly
enriched in the immune related pathways. Two genes, S100A8 and TYROBP, had consistent changes in expression in
both individual and pooled sequencing datasets and were nominally significant in gene-based association analysis.
Conclusions: Integration of gene expression and pathway analyses with genome-wide association may be an
efficient approach to identify risk genes for schizophrenia.

Background
Schizophrenia is characterized by delusions, hallucinations,
and deficits in cognitive function. Over the years, epidemiologic studies have accumulated significant evidence
that many genetic factors play important roles in both
symptomatology and etiology. Recent genetic studies,
including genome-wide association (GWA) studies, have
identified several promising candidate genes and loci. One
of the most consistent findings in GWA studies is the
major histocompatibility (MHC) region in 6p [1-3]. This
finding strongly implicates the immune system as being
involved in the development of schizophrenia. Other findings include candidate genes functioning in cell adhesion
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[4-6], migration [4,7] and apoptosis [8,9]. Except the findings from rare copy number variations [10-13], the effects
of individual genes overall are modest or weak. These
results suggest that many genes with moderate or small
effects may be involved in schizophrenia [14]. It is difficult
to identify these genes without increased sample sizes and
better analysis of phenotype. Integration of other functional studies or utilization of high throughput technologies may increase the power to detect other schizophrenia
candidate genes.
Whole genome mRNA sequencing (RNA-Seq, or transcriptome sequencing) allows for the comprehensive survey of all the mRNAs in a sample. This platform is the
fruit of recently developed high-throughput DNA sequencing technology [15,16], and has produced exciting results
in the study of various diseases [17-19]. In this experiment,
we applied the RNA-Seq technology to study schizophrenia. Specifically, we aimed to understand the dysregulation
in schizophrenia at higher levels of biological structure
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and to integrate gene expression data to facilitate the identification of promising candidate genes. To accomplish
these goals, we sequenced the blood mRNAs isolated from
3 schizophrenic patients and 3 matched healthy controls.
We verified the differentially expressed genes (DEGs) in 2
independent pooled samples. We further examined the
association of the discovered DEGs using GWA data from
the molecular genetics of schizophrenia (MGS) study.
Two differentially expressed genes, S100A8 and TYROBP,
reached nominal significance in gene-based association
analysis.

Materials and methods
Subjects, sample preparation and sequencing

Schizophrenia patients were recruited from the pool of
diagnosed schizophrenia patients of the inpatient unit of
the VA Medical Center of Western New York (WNY) and
from the Buffalo Psychiatric Center inpatient unit. All
enrolled patients met the DSM-IV criteria for schizophrenia based on the examination of psychiatric case records
and clinical interviews by at least two experienced psychiatrists. The healthy individuals were recruited though VA
employees and advertisements in the local media. Individuals with a family history of schizophrenia or other
major psychiatric disorders were excluded. A total of 26
subjects were included in this study. All subjects gave
informed consent to participate in the study. The protocol
and consent form were approved by the institutional
review boards at the VA WNY Health Care System and
New York State Office Mental Health.
Blood samples were collected with a 10 ml Vacutainer,
Acid Citrate Dextrose (ACD) tube. Lymphocytes were
prepared using isolymph (a diagnostic reagent used to
separate lymphocytes from blood). Each 100 ml of isolymph contains 5.7 grams of Ficoll 400 and 9.0 grams of
Diatrizoate Sodium) in a density gradient [20]. Ten ml of
whole blood was diluted with equal volume RPMI and
mixed by pipetting. Three milliliter of isolymph was
transferred to a 15 ml Falcon conical bottom tube and
4 ml of diluted blood was carefully layered on top of the
isolymph. The samples were centrifuged at 1640 rpm for
30 minutes. Lymphocytes were collected at the interface
between the two layers by a sterile 1 ml pipette. The lymphocytes were mixed with 3 volumes of RPMI and centrifuged at 1400 rpm for 10 minutes. The supernatant was
then removed. The lymphocytes were re-suspended in
Cold Freeze Medium (60% RPMI 1640, 10% DMSO, 30%
heat inactivated FCS) at a lymphocytes density of 6-12 ×
106 cells/ml. The lymphocytes were distributed to NUNC
plastic cryopreservation vials for long term storage. The
vials were first placed in the cryo freezing container and
stored at -80°C for at least 4 hours and then transferred
to liquid nitrogen for final storage.
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RNA was prepared from the frozen lymphocytes. Total
RNA was extracted using the Mico-to-Midi Total RNA
Purification System (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. The total RNA concentration and purity were determined spectrophotometrically
at 260 nm and 280 nm in the Functional Genomics Shared
Resource (FGSR) in Vanderbilt University.
MRNA capture, cDNA conversion, sizing, and library
construction were performed using kits from the Illumina
Company and by following the manufacture’s recommended procedures. For RNA-Seq application, individual
libraries were constructed for 3 schizophrenia patients, 3
controls, and 2 pools (10 subjects/pool) of schizophrenia
patients and controls. Each library was loaded into a single
lane of the Illumina Genome Analyzer II flow cell. For 3
cases and 3 controls, we performed paired-end sequencing
while for pooled samples, we performed single-end
sequencing. Image analysis and base-calling were performed by the Genome Analyzer Pipeline version 2.0 with
default parameters [21]. Library construction and RNA
sequencing was performed in the Genome Technology
Core (GTC) in Vanderbilt University.
Data process and analysis

After obtaining the short reads, we performed a series of
quality checks, including quality score evaluation using
program HTSeq [22] and marking duplicate reads by
using software SAMTools [23]. All reads were independently aligned to a single reference file consisting of all
human transcripts and the human genome in the UCSC
genome assembly hg18 (NCBI build 36.1) by using
TopHat (Version 1.0.10) [24]. The aligned sequences were
evaluated with SAMTools for capture efficiency in order
to ensure no artificial fragment representation (as assessed
by fragment position distribution). We ran TopHat in the
‘paired-end mode’ with the minimum distance between
paired-end reads of 120 bp, a maximum distance of
500,000 bp, and default settings of other parameters (e.g.,
no more than two mismatches between read and reference
were allowed in the first 28 bp (5’ end) of the read).
To obtain an accurate measure of transcript abundance, we only used the reads that were uniquely mapped
to the human genome. Since the sequence reads were
paired-end, we quantified expression levels of all transcripts in each subject according to the fragments per
kilobase of exon per million fragments mapped (FPKM),
which was calculated by the software Cufflinks [25].
FPKM is a similar measurement to RPKM, which measures gene expression in Reads Per exon Kilobase per
Million mapped reads (RPKM). RPKM has been used to
normalize measurement of exon read density and allows
transcript levels to be compared both within and between
samples [25,26].
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Considering that RNA-Seq mainly estimates exon
expression and that most genes have multiple transcripts,
it is necessary to determine how to estimate gene expression level based on transcript expression data. In our
study, we employed a simple strategy: we first identified
the differentially expressed transcripts (DETs) and then
considered the unique genes of these transcripts as differentially expressed genes (DEGs) for further functional
analysis.
To improve the reliability and comparability of differential expression analysis, we only examined the expression difference of those transcripts with FPKM value > 5
in all individually sequenced patients and controls [25].
Using these transcripts, we performed Fisher’s exact test
to identify transcripts with significantly differential
expression between patients and controls [27-29]. For
each transcript, we constructed a 2 × 2 contingency
table, which included four FPKM values: n, N-n, r, R-r
where n is the sum of FPKM values of a given transcript
in 3 cases, N is the sum of FPKM values of all transcripts in cases, r is the sum of FPKM values of the
given transcript in 3 controls, and R is the sum of the
FPKM values of all transcripts in controls. To determine
the expression change direction, we used “greater” or
“less” parameters in the one-tailed Fisher’s exact test to
find the up-regulated transcripts or down-regulated
transcripts respectively. Next, we controlled the type 1
errors by Bonferroni correction for the number of tests
performed. A transcript was considered differentially
expressed if the Bonferroni adjusted P-value was less
than 0.05.
For data generated from pooled samples, we performed
the same data processing and analysis as the individually
sequenced samples except for using single-end mode to
perform mapping of the reference sequence.
Functional analysis

To assess the function of the DEGs that we identified, we
conducted pathway enrichment tests for the DEGs using
the online tool WebGestalt (version 2) [30]. We used all
pathways in the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database. We selected those pathways
having adjusted P-values of less than 0.01 calculated by
the hypergeometric test followed by the Benjamini-Hochberg method [31], which was implemented in WebGestalt.
To make the analysis biologically meaningful, we considered only those KEGG pathways containing 5 or more
DEG genes.
To further systematically determine canonical signaling
pathways and molecular networks that the DEGs might
involve, we performed the pathway/network enrichment
analysis using the Ingenuity Pathway Analysis (IPA) tool
from the Ingenuity Systems [32]. For canonical signaling
pathway analysis, given a list of genes, a right-tailed
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Fisher’s exact test was performed for the enrichment of
these genes in its hand-curated canonical pathway database. Here, the P-value calculated for a pathway measures
the probability of being randomly selected from all of the
curated pathways. To control the error rate in the analysis, IPA also provided a corrected P-values to identify the
most significant results in IPA’s canonical pathways
based on the Benjamini-Hochberg method [31]. This tool
allowed us to identify the signaling pathways in which
the DEGs were enriched. In our study, we used a cut-off
of the corrected P-value less than 0.05 (or score > 1.30,
here score = -log P) to define the significant pathways.
For network enrichment, the DEGs were overlaid onto a
global molecular network (GMN) developed based on
the Ingenuity Pathways Knowledge Base, in which functional relationships such as activation, chemical-protein
interaction, expression, inhibition and regulation of binding were manually curated. Subnetworks of genes were
then extracted from the GMN based on their connectivity using the algorithm developed by IPA [33]. For each
subnetwork, a likelihood score, which measures the probability of the DEGs being found in the same subnetwork
by chance, was transformed from the P- values calculated
by Fisher’s exact test. Additionally, the IPA assigned the
top 3 biological functions for each network it identified.
Gene-based genome-wide association analysis

The RNA-Seq application produced a list of differentially expressed genes in schizophrenia. We examined
whether genetic variants in these DEGs harbored association signals. We conducted a gene-based GWA analysis using the MGS dataset for schizophrenia. We
obtained this dataset from dbGaP under the protocol of
“Genetic study of schizophrenia, nicotine dependence
and other comorbid psychiatric disorders” by X.C. For
each gene, its association P-value with schizophrenia
was estimated using the VEGAS (Versatile Gene-based
Association Study) software package [34].

Results
An overview of RNA-Seq data

In this study, we conducted genome-wide RNA sequencing for 6 individual samples and 2 pooled samples. The
data from individually sequenced subjects was used for
the initial identification of DEGs, while the pooled data
was used to validate these DEGs.
For the 6 individually sequenced samples, after filtering
by quality score, we generated an average of 8.7 million
pairs of 43-bp paired-end reads per sample. The quality
scores of the reads were satisfactory (Figure S1), of which
90.3% of the called bases had a Phred score ≥ 30. Table 1
shows the mapping statistics of the fragments. For each
subject, an average of approximately 85.1% of the reads
could be mapped to the human reference genome.
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Table 1 Statistics of the number of fragments sequenced, aligned and mapped using TopHat
Sample

Sequenced
fragmentsa

All mapped
fragments (%)

Uniquely mapped
fragments (%)b

Singleton
fragments (%)c

Spliced
fragments (%)d

Multi-loci mapped
fragments (%)

1295ZZ-4

10,114,082

84.5

45.2

24.9

3.8

26.1

1295ZZ-9

6,152,569

82.0

46.1

24.5

3.3

26.2

1295ZZ-13

9,263,358

86.5

50.6

25.0

3.2

21.2

1295ZZ-21

9,287,780

85.8

50.7

25.1

3.3

20.9

1295ZZ-32

8,911,007

85.4

48.5

26.3

4.0

21.2

1295ZZ-36

8,211,577

86.6

50.7

23.3

3.2

22.8

Control

Case

a

Each fragment has two short sequence reads.
For uniquely mapped fragments, both of the two reads could be uniquely mapped to a unique location in the reference genome.
c
For singleton fragments, only one of the two reads could be mapped to the reference genome.
d
For spliced fragments, at least one of the two reads could be mapped across a splicing junction.
b

Among the mapped sequences, ~48.6% of the read pairs
were uniquely mapped to the human genome as properly
aligned fragments. This is similar to the output of other
RNA-Seq sequencing studies [35,36].
These reads were used to estimate transcript expression of all 6 samples. Table 2 shows the transcripts
detected by RNA-Seq in subjects and mapped genes
with FPKM values and coverage. Of the 33,599 transcripts and 32,797 genes annotated in the UCSC hg18,
we detected 18,226 (54.2%) transcripts (FPKM > 0),
which mapped to 14,929 (45.5%) unique genes. Among
these transcripts, on average, 7223 (41.7%) had their
FPKM values higher than 5.
For the pooled samples, we generated a total of 26.2
million reads for the cases, of which 92.05% were
mapped to the human reference genome, and 28.4 million reads for the controls, of which 91.29% were

mapped. The resulting expression on transcription level
and gene level were summarized in Table 2.
Identification of differentially expressed genes

To identify the DEGs between the cases and controls, we
used only those transcripts with FPKM values > 5.0 in all
the 6 subjects. With this criterion, 4715 transcripts were
included for differential expression analysis. Using Fisher’s
exact test, a total of 206 transcripts reached significance
after Bonferroni correction (Table S1). Among these transcripts, 123 (mapped to 118 unique genes) were significantly down-regulated and 83 (mapped to 80 unique
genes) were significantly up-regulated. In addition to transcripts expressed in both cases and controls, there were
transcripts detected only in the cases or controls. Based on
the FPKM distribution (Figure S2), transcripts exclusively
expressed in either cases or controls with FPKM > 2.0

Table 2 Statistics of the number of transcripts and genes detected
Sample

Number of transcripts Number of genes FPKMa (mean ± sd) Coverageb (mean ± sd) Number of genes with FPKM > 5

Control
1295-ZZ-4

18,675

15,176

15.28 ± 85.28

8.54 ± 45.80

7876

1295-ZZ-9

17,134

14,330

14.36 ± 67.49

4.66 ± 21.03

6832

1295-ZZ-13 18,638

15,205

13.52 ± 68.07

7.06 ± 34.89

7507

1295-ZZ-21 18,274

14,883

14.86 ± 84.98

7.72 ± 43.89

6903

1295-ZZ-32 18,796

15,315

14.59 ± 167.18

7.14 ± 74.54

7359

1295-ZZ-36 17,837

14,668

11.84 ± 55.17

5.41 ± 24.17

6863

Case

Pooled control

22,463

17,880

10.65 ± 70.63

18.04 ± 119.42

6134

Pooled case

22,256

17,620

11.67 ± 79.45

21.16 ± 143.79

6267

a

For individually sequenced dataset, we used FPKM (Fragments Per Kilobase of exon per Million fragments mapped) to estimate transcript expression.
The coverage was calculated based on the unit of transcript.

b
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were included in the pathway and functional analyses.
There were 12 transcripts exclusively expressed in cases
(mapped to 12 unique genes) and 8 transcripts exclusively
expressed in controls (mapped to 8 unique genes) (Table
S2). Thus, we obtained a total of 218 genes differentially
expressed among the 6 sequenced subjects.
Validation and functional enrichment analysis of the DEGs

To validate the DEGs discovered from the individually
sequenced dataset, we conducted similar differential
expression analyses for the pooled dataset (see Materials
and methods). There were 155 transcripts reaching nominal significance, of which 84 were up-regulated (mapped
to 78 genes) and 72 were down-regulated (mapped to 68
unique genes). Of the 218 DEGs identified from the individually sequenced dataset, 9 were up-regulated (GNAS,
GNLY, HBA1, HBB, NCRNA00188, NEAT1, NFKB2,
S100A8, and SNHG5) and 10 were down-regulated genes
(CD74, CXCR4, LGALS2, LYZ, PF4, PIK3IP1, RBM38,
RPL30, SCO2, and TYROBP) that were found differentially expressed between cases and controls in the pooled
dataset (with the same direction of gene expression
change).
We conducted KEGG pathway profiling of these 218
DEGs. The results are shown in Table 3. Of the pathways
enriched in these 218 genes, the most noticeable ones are
involved in the immune and inflammation systems (antigen processing, cell adhesion molecules, hematopoietic
cell lineage, systemic lupus erythematosus, chemokine
signaling pathway, intestinal immune network for IgA
production, toll-like receptor signaling pathway, T cell

receptor signaling pathway, B cell receptor signaling
pathway, Cytokine-cytokine receptor interaction, etc).
Interestingly, the cell adhesion molecules pathway
(CAMs, KEGG pathway ID hsa04514, adjusted P value =
5.78 × 10 -9 , Table 3) was the only pathway that was
found to be significantly associated with both schizophrenia and bipolar disorder in a recent pathway analysis of
schizophrenia and bipolar disorder GWAS datasets [37].
It was also highlighted in our recent pathway analysis
using a generalized additive model for correction of gene
length biases and other two methods (ALIGATOR and
hypergeometric test) (unpublished data). Upon our
further examination, we found 10 DEG genes in the
CAMs pathway. Among the 10 genes, 8 were down-regulated (CD4, HLA-DPA1, HLA-DRA, HLA-DRB1, ITGB2,
PECAM1, SELL and VCAN) and two were up-regulated
(CD8A and ITGB7). Among the 8 down-regulated genes,
three (HLA-DPA1, HLA-DRA and HLA-DRB1) were in
the MHC region (chr6:20,000,000-40,000,000) (Table S3).
For the 19 genes differentially expressed in both datasets, four are involved in immune systems (CXCR4,
NFKB2, PF4, and TYROBP). In our KEGG pathway
enrichment analysis, we found several pathways overrepresented in these genes including “Chemokine signaling
pathway” and “Cytokine-cytokine receptor interaction,”
both of which were found significantly overrepresented
in the 218 genes (Table 3). We further examined the
pathways that were significantly overrepresented in these
genes using IPA tools. The most significant pathways
were “MIF-mediated glucocorticoid regulation,” “MIF
regulation of innate immunity,” “TREM1 signaling,” and

Table 3 KEGG pathways significantly enriched in the 218 differentially expressed genes
KEGG pathway
Antigen processing and presentation

Number of genes (%)
14 (6.42)

Nominal P-valuea

Adjusted P-valueb

-18

1.58 × 10-16

-11

9.27 × 10

Lysosome
Cell adhesion molecules (CAMs)

11 (5.05)
10 (4.59)

1.07 × 10
9.31 × 10-10

9.09 × 10-11
5.28 × 10-9

Hematopoietic cell lineage

8 (3.67)

9.68 × 10-9

4.11 × 10-8

-8

2.44 × 10-7

-7

8.86 × 10-7

-7

8.86 × 10-7

-6

8.27 × 10-6

-6

1.65 × 10-5

-5

MAPK signaling pathway
Chemokine signaling pathway
Systemic lupus erythematosus
Intestinal immune network for IgA production
Toll-like receptor signaling pathway

11 (5.05)
9 (4.13)
8 (3.67)
5 (2.29)
6 (2.75)

7.17 × 10
3.31 × 10
3.65 × 10
3.89 × 10
8.76 × 10

T cell receptor signaling pathway
Epithelial cell signaling in Helicobacter pylori infection

6 (2.75)
5 (2.29)

1.29 × 10
1.79 × 10-5

2.19 × 10-5
2.77 × 10-5

Leukocyte transendothelial migration

6 (2.75)

2.13 × 10-5

3.02 × 10-5

5 (2.29)

-5

3.77 × 10-5

-5

B cell receptor signaling pathway

2.88 × 10

Ribosome

5 (2.29)

6.23 × 10

7.56 × 10-5

Cytokine-cytokine receptor interaction

6 (2.75)

0.0017

0.0019

Metabolic pathways

13 (5.96)

0.0023

0.0024

Pathways in cancer

6 (2.75)

0.0049

0.0049

Nominal P-value was calculated by hypergeometric test.
Adjusted P-values was corrected of nominal P-values by Benjamini-Hochberg multiple testing correction.

a

b
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“Induction of apoptosis by HIV1”. MIF (macrophage
migration inhibitory factor) is a unique counter-regulator
of immunosuppressive and anti-inflammatory activities
of glucocorticoids. Consistent with the results of 218
genes, all of these pathways are related to immune and
inflammation systems. Furthermore, we conducted network analysis using IPA. Figure 1 shows the top network
overrepresented in these genes, in which the top three
functions are “Molecular transport,” “Cellular movement,” and “Hematological system development and
function.” Note that several genes in Figure 1 are potentially interesting like CD74, S100A8, Akt, IL12, TYROBP,
HBB and HBA1. Among them, CD74 encodes a Type II
transmembrane protein, which is a binding protein for
MIF and an essential protein for MIF-induced activation
of extracellular signal-regulated kinase-1/2MAP kinase
cascade, cell proliferation and apoptosis [38].
Gene-based association analyses of DEGs

One of the objectives of our RNA-Seq experiments was to
test whether differentially expressed genes were enriched
for association signals in GWA studies. Towards this goal,
we conducted gene-based GWA analysis using the MGS
dataset and the VEGAS method [34].This analysis produced a P value for each gene by considering gene’s linkage disequilibrium information from the HapMap
populations. We matched the 218 DEGs with those genes
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from the association analysis. Of the 218 genes, 21 had
their P values less than 0.05 (Table 4). This was 2-fold
enrichment than the expected (P = 0.0025). Five genes
(SELL [39], HLA-DRB1 [40], CEBPD [41], HSPA5 [42],
and NRGN [3]) from the matched list had been previously
studied for schizophrenia with positive association signals,
the rest of the genes were involved in immune responses
or other neuronal diseases. Two genes, S100A8 and TYROBP, were differentially expressed in both the individual
and pooled sequencing datasets.

Discussion
Recent studies have shown that most genetic factors predisposing to schizophrenia have only a modest effect.
GWA studies alone seem insufficient to identify the
majority of these genetic factors. Expression level is an
index of function of genes and may be useful for identifying risk genes for schizophrenia at the transciptomic level.
In this study, we took advantage of recently available next
generation sequencing technologies (i.e., RNA-Seq) to
sequence poly-A tailed mRNAs from blood samples of 6
individuals and 2 pools of schizophrenia patients and controls. In the 6 individually sequenced samples, we found
218 genes showing differentially expression between cases
and controls. Among these genes, 19 were nominally significant at the expression level in the 2 pooled samples. In
our IPA analysis, we found that MIF regulation of innate

Figure 1 The top network overrepresented by the 19 concordantly differentially expressed genes. The functions of this network include
“molecular transport,” “cellular movement,” and “hematological system development and function“. Nodes in red indicate up-regulation in the cases
and nodes in green indicate down-regulation.
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Table 4 Association of differentially expressed genes
with schizophrenia
Gene
symbol

Association Pvaluea

Gene function

LYN

0.0025

Schizophrenia candidate

HLA-DRB1

0.0065

Schizophrenia candidate

SAMHD1

0.0112

Aicardi-Goutières syndrome

SELL
S100A8

0.0114
0.0140

Schizophrenia candidate
Immune response/disease

CEBPD

0.0179

Schizophrenia candidate

ALDOA

0.0215

Creutzfeldt-Jakob disease
candidate

CTSS

0.0223

Immune response/disease

NRGN

0.0263

Schizophrenia candidate

HLA-DRA

0.0267

Schizophrenia candidate

C1orf38

0.0269

Breast cancer

TRIM8

0.0272

Ubiquitylation

NKG7
MCL1

0.0283
0.0302

Immune response/diseases
Immune response/disease

FCN1

0.0363

Rheumatoid arthritis candidate

TYROBP

0.0367

Immune response/diseases

DDIT4

0.0410

Parkinson’s disease candidate

FCGR3B

0.0434

Immune response/disease

LTA4H

0.0454

Myocardial infarction candidate

ITM2B

0.0480

Alzheimer’s disease candidate

HSPA5

0.0493

Schizophrenia candidate

a

The association was examined using the MGS GWAS dataset (see Methods)
by the VEGAS method.

immunity and TREM1 signaling were highly enriched in
these 19 genes. Furthermore, of the 218 DEGs, 21 reached
nominal significance in gene-based association analysis of
the MGSGWAS dataset. Nineteen of these 21 genes are
directly involved in immune response/diseases, or have
been studied for candidates for schizophrenia and other
neuronal diseases. Two genes, S100A8 and TYROBP,
showed the same direction of expression changes in the
individual and pooled sequencing datasets, and they also
reached nominal significance in gene-based association
analysis.
S100A8, also called MRP-8, encodes a calcium binding
protein involved in inflammatory responses. It has been
implicated in rheumatoid arthritis [43], systemic lupus
erythematosus [44] and cancers [45,46]. Intriguingly, rheumatoid arthritis may be correlated with schizophrenia
[47,48]. TYROBP, also known as DAP12, encodes an
immunoreceptor adaptor protein that plays a key role in
osteoclast differentiation and maturation [49,50]. Mutations in this gene lead to the Nasu-Hakola disease [51-54],
a rare autosomal recessive disorder characterized by bone
cyst and presenile dementia. In addition to their functions
in the immune system, both genes are expressed in
human brain. S100A8 shows elevated expression in cerebral ischemia [55] and posttraumatic brain injuries [56]. In
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a mouse model study, S100A8 expression increases significantly after chronic treatment with the antipsychotic drug
olanzapine, which is used primarily to treat schizophrenia
and bipolar disorder patients. TYROBP is implicated in the
developmental neuronal death in hippocampus [57],
impaired glutamatergic synaptic functions [58] and brain
myelination [59]. All of these factors have been suspected
to be involved in schizophrenia. TYROBP knockout mouse
studies reveal deficits in cognitive functions and prepulse
inhibition [49], symptoms that have been manifested in
many schizophrenia patients. However, neither gene has
been studied directly for schizophrenia. They may be
novel candidates for the disease.
Glatt et al [60] applied microarray techniques to compare gene expression of peripheral blood cells (PBCs) and
the dorsolateral prefrontal cortex (DLPFC) of the brain to
identify risk factors for schizophrenia. They detected 123
differentially expressed genes in the blood samples.
Among our 218 DEGs, 13 genes had the same direction of
expression changes as reported by Glatt et al. Specifically,
eight genes were down-regulated (CD74, FCN1, FGR,
HLA-DPA1, HLA-DRB1, IL10RA, PSAP, and ZFP36L2)
and five were up-regulated (GOS2, HBA1, HBA2, HBB,
and IL8). The overlap of 13 genes with same direction of
expression change is unlikely by chance considering they
were selected from a genome-wide gene pool (P-value =
5.36 × 10-6). Interestingly, among the eight down-regulated genes, CD74 was consistently found down- regulated
in three gene expression data sets (our individual sample,
our pooled sample, and PBC sample in the Glatt et al
study). Gene CD74 encodes a protein in MHC and is
located in a region implicated by genome-wide linkage
meta-analyses [61,62]. Additionally, the MHC locus on
chromosome 6p was the most consistent finding from
GWA studies [1-3]. Another gene, HLA-DRB1, also
located in the MHC locus, was found to be differentially
expressed in three data sets (the individual RNA-Seq dataset in this study, the PBC and DLPFC datasets in the Glatt
et al study). HLA-DRB1 has been reported for positive
association with schizophrenia [63,64]. We also found that
SNPs influencing the expression of HLA-DRB1 (expression
quantitative trait loci - eQTLs) were significantly associated with schizophrenia in the CATIE and MGS datasets
(unpublished data). This result provides empirical evidence that a combination of GWA data and eQTL analysis
may be effective to identify risk genes.

Conclusion
This exploratory study aims at evaluating how RNA-Seq
can be used to facilitate the identification of risk genes for
complex diseases such as schizophrenia. Limitations
include 1) the small number of subjects sequenced in this
study and 2) only one pair of pooled samples was available
to confirm the DEGs discovered in the individually
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sequenced dataset. Note that many RNA-Seq studies published in the past three years were based on a small number of samples (n ≤ 3) [65]. Due to these limitations, many
genes potentially involved in schizophrenia could not be
detected in the individually sequenced dataset and none of
the genes in the pooled sample dataset reached significance after Bonferroni or false discovery rate correction.
For these reasons, we selected to use those genes that
reached nominal significance (one tailed test P < 0.1 for
genes showing the same direction of expression changes)
to verify the DEGs from the individually sequenced dataset. This may lead to the inclusion of some false positives
in the 19 genes. At this time, we are unable to distinguish
the true positives from the false ones. Since we observed
19 overlapping genes for the 218 DEGs, exceeding the
expected number by chance, collectively, a majority of
these 19 genes are unlikely to be false positives. The pathways and processes identified based on these 19 genes are
likely reliable, and should provide important insights on
the genes whose expression might be involved in the
development of schizophrenia. Based on the same rationale, the list of genes identified by gene-based analysis
may have false positives, but most of the genes could be
considered promising candidates for schizophrenia. These
promising candidates warrant further validation.
In summary, by combining high throughput RNA
sequencing and GWA data, we have identified a list of
candidate genes for schizophrenia despite our small
sample size. These genes are enriched in the pathways
and processes of the immune system. Our study demonstrates that integration of GWAS and gene expression
can provide valuable information to prioritize candidates
for future studies.

Additional material
Additional file 1: This file includes the following figures and tables.
Figure S1 - Median Phred score vs. base position (cycle). Figure S2 Distribution of the average FPKM values in the controls and cases. FPKM
represents for fragments per kilobase of exon per million fragments
mapped. Table S1 - Differentially expressed genes between schizophrenia
patients and controls. Table S2 - Genes exclusively expressed in cases or
controls. Table S3 - CAMs genes located in the MHC regions
(chr6:20,000,000-40,000,000).
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